# Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

> **NCT04876248** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Belantamab Mafodotin
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04876248
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876248, "Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04876248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*